Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelodysplastic Syndrome Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Alkylating Agents
1.2.3 Cytotoxic Antibiotics
1.2.4 Topoisomerase Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome Market Perspective (2018-2033)
2.2 Myelodysplastic Syndrome Growth Trends by Region
2.2.1 Global Myelodysplastic Syndrome Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Myelodysplastic Syndrome Historic Market Size by Region (2018-2023)
2.2.3 Myelodysplastic Syndrome Forecasted Market Size by Region (2024-2033)
2.3 Myelodysplastic Syndrome Market Dynamics
2.3.1 Myelodysplastic Syndrome Industry Trends
2.3.2 Myelodysplastic Syndrome Market Drivers
2.3.3 Myelodysplastic Syndrome Market Challenges
2.3.4 Myelodysplastic Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome Players by Revenue
3.1.1 Global Top Myelodysplastic Syndrome Players by Revenue (2018-2023)
3.1.2 Global Myelodysplastic Syndrome Revenue Market Share by Players (2018-2023)
3.2 Global Myelodysplastic Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myelodysplastic Syndrome Revenue
3.4 Global Myelodysplastic Syndrome Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome Revenue in 2022
3.5 Myelodysplastic Syndrome Key Players Head office and Area Served
3.6 Key Players Myelodysplastic Syndrome Product Solution and Service
3.7 Date of Enter into Myelodysplastic Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myelodysplastic Syndrome Breakdown Data by Type
4.1 Global Myelodysplastic Syndrome Historic Market Size by Type (2018-2023)
4.2 Global Myelodysplastic Syndrome Forecasted Market Size by Type (2024-2033)
5 Myelodysplastic Syndrome Breakdown Data by Application
5.1 Global Myelodysplastic Syndrome Historic Market Size by Application (2018-2023)
5.2 Global Myelodysplastic Syndrome Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Myelodysplastic Syndrome Market Size (2018-2033)
6.2 North America Myelodysplastic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Myelodysplastic Syndrome Market Size by Country (2018-2023)
6.4 North America Myelodysplastic Syndrome Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myelodysplastic Syndrome Market Size (2018-2033)
7.2 Europe Myelodysplastic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Myelodysplastic Syndrome Market Size by Country (2018-2023)
7.4 Europe Myelodysplastic Syndrome Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myelodysplastic Syndrome Market Size (2018-2033)
8.2 Asia-Pacific Myelodysplastic Syndrome Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2018-2023)
8.4 Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myelodysplastic Syndrome Market Size (2018-2033)
9.2 Latin America Myelodysplastic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Myelodysplastic Syndrome Market Size by Country (2018-2023)
9.4 Latin America Myelodysplastic Syndrome Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myelodysplastic Syndrome Market Size (2018-2033)
10.2 Middle East & Africa Myelodysplastic Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2018-2023)
10.4 Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Detail
11.1.2 Celgene Business Overview
11.1.3 Celgene Myelodysplastic Syndrome Introduction
11.1.4 Celgene Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.1.5 Celgene Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Myelodysplastic Syndrome Introduction
11.2.4 Novartis Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 Otsuka
11.3.1 Otsuka Company Detail
11.3.2 Otsuka Business Overview
11.3.3 Otsuka Myelodysplastic Syndrome Introduction
11.3.4 Otsuka Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.3.5 Otsuka Recent Development
11.4 Actinium Pharmaceuticals
11.4.1 Actinium Pharmaceuticals Company Detail
11.4.2 Actinium Pharmaceuticals Business Overview
11.4.3 Actinium Pharmaceuticals Myelodysplastic Syndrome Introduction
11.4.4 Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.4.5 Actinium Pharmaceuticals Recent Development
11.5 Acceleron Pharma
11.5.1 Acceleron Pharma Company Detail
11.5.2 Acceleron Pharma Business Overview
11.5.3 Acceleron Pharma Myelodysplastic Syndrome Introduction
11.5.4 Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.5.5 Acceleron Pharma Recent Development
11.6 Bellicum Pharmaceuticals
11.6.1 Bellicum Pharmaceuticals Company Detail
11.6.2 Bellicum Pharmaceuticals Business Overview
11.6.3 Bellicum Pharmaceuticals Myelodysplastic Syndrome Introduction
11.6.4 Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.6.5 Bellicum Pharmaceuticals Recent Development
11.7 Cornerstone Pharmaceuticals
11.7.1 Cornerstone Pharmaceuticals Company Detail
11.7.2 Cornerstone Pharmaceuticals Business Overview
11.7.3 Cornerstone Pharmaceuticals Myelodysplastic Syndrome Introduction
11.7.4 Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.7.5 Cornerstone Pharmaceuticals Recent Development
11.8 CTI BioPharma
11.8.1 CTI BioPharma Company Detail
11.8.2 CTI BioPharma Business Overview
11.8.3 CTI BioPharma Myelodysplastic Syndrome Introduction
11.8.4 CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.8.5 CTI BioPharma Recent Development
11.9 Onconova Therapeutics
11.9.1 Onconova Therapeutics Company Detail
11.9.2 Onconova Therapeutics Business Overview
11.9.3 Onconova Therapeutics Myelodysplastic Syndrome Introduction
11.9.4 Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.9.5 Onconova Therapeutics Recent Development
11.10 Strategia Therapeutics
11.10.1 Strategia Therapeutics Company Detail
11.10.2 Strategia Therapeutics Business Overview
11.10.3 Strategia Therapeutics Myelodysplastic Syndrome Introduction
11.10.4 Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.10.5 Strategia Therapeutics Recent Development
11.11 KaloBios Pharmaceuticals
11.11.1 KaloBios Pharmaceuticals Company Detail
11.11.2 KaloBios Pharmaceuticals Business Overview
11.11.3 KaloBios Pharmaceuticals Myelodysplastic Syndrome Introduction
11.11.4 KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.11.5 KaloBios Pharmaceuticals Recent Development
11.12 Kiadis Pharma
11.12.1 Kiadis Pharma Company Detail
11.12.2 Kiadis Pharma Business Overview
11.12.3 Kiadis Pharma Myelodysplastic Syndrome Introduction
11.12.4 Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.12.5 Kiadis Pharma Recent Development
11.13 Mirati Therapeutics
11.13.1 Mirati Therapeutics Company Detail
11.13.2 Mirati Therapeutics Business Overview
11.13.3 Mirati Therapeutics Myelodysplastic Syndrome Introduction
11.13.4 Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.13.5 Mirati Therapeutics Recent Development
11.14 Astex
11.14.1 Astex Company Detail
11.14.2 Astex Business Overview
11.14.3 Astex Myelodysplastic Syndrome Introduction
11.14.4 Astex Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.14.5 Astex Recent Development
11.15 Celator Pharmaceuticals
11.15.1 Celator Pharmaceuticals Company Detail
11.15.2 Celator Pharmaceuticals Business Overview
11.15.3 Celator Pharmaceuticals Myelodysplastic Syndrome Introduction
11.15.4 Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.15.5 Celator Pharmaceuticals Recent Development
11.16 Eli-lilly
11.16.1 Eli-lilly Company Detail
11.16.2 Eli-lilly Business Overview
11.16.3 Eli-lilly Myelodysplastic Syndrome Introduction
11.16.4 Eli-lilly Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.16.5 Eli-lilly Recent Development
11.17 Sunesis Pharmaceuticals
11.17.1 Sunesis Pharmaceuticals Company Detail
11.17.2 Sunesis Pharmaceuticals Business Overview
11.17.3 Sunesis Pharmaceuticals Myelodysplastic Syndrome Introduction
11.17.4 Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.17.5 Sunesis Pharmaceuticals Recent Development
11.18 Targazyme
11.18.1 Targazyme Company Detail
11.18.2 Targazyme Business Overview
11.18.3 Targazyme Myelodysplastic Syndrome Introduction
11.18.4 Targazyme Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.18.5 Targazyme Recent Development
11.19 Gamida Cell
11.19.1 Gamida Cell Company Detail
11.19.2 Gamida Cell Business Overview
11.19.3 Gamida Cell Myelodysplastic Syndrome Introduction
11.19.4 Gamida Cell Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.19.5 Gamida Cell Recent Development
11.20 GlaxoSmithKline
11.20.1 GlaxoSmithKline Company Detail
11.20.2 GlaxoSmithKline Business Overview
11.20.3 GlaxoSmithKline Myelodysplastic Syndrome Introduction
11.20.4 GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.20.5 GlaxoSmithKline Recent Development
11.21 Sumitomo Dainippon Pharma
11.21.1 Sumitomo Dainippon Pharma Company Detail
11.21.2 Sumitomo Dainippon Pharma Business Overview
11.21.3 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Introduction
11.21.4 Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.21.5 Sumitomo Dainippon Pharma Recent Development
11.22 TetraLogic Pharmaceuticals
11.22.1 TetraLogic Pharmaceuticals Company Detail
11.22.2 TetraLogic Pharmaceuticals Business Overview
11.22.3 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Introduction
11.22.4 TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023)
11.22.5 TetraLogic Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Myelodysplastic Syndrome Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Alkylating Agents
Table 3. Key Players of Cytotoxic Antibiotics
Table 4. Key Players of Topoisomerase Inhibitors
Table 5. Key Players of Others
Table 6. Global Myelodysplastic Syndrome Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Myelodysplastic Syndrome Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Myelodysplastic Syndrome Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Myelodysplastic Syndrome Market Share by Region (2018-2023)
Table 10. Global Myelodysplastic Syndrome Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Myelodysplastic Syndrome Market Share by Region (2024-2033)
Table 12. Myelodysplastic Syndrome Market Trends
Table 13. Myelodysplastic Syndrome Market Drivers
Table 14. Myelodysplastic Syndrome Market Challenges
Table 15. Myelodysplastic Syndrome Market Restraints
Table 16. Global Myelodysplastic Syndrome Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Myelodysplastic Syndrome Market Share by Players (2018-2023)
Table 18. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome as of 2022)
Table 19. Ranking of Global Top Myelodysplastic Syndrome Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Myelodysplastic Syndrome Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Myelodysplastic Syndrome Product Solution and Service
Table 23. Date of Enter into Myelodysplastic Syndrome Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Myelodysplastic Syndrome Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Myelodysplastic Syndrome Revenue Market Share by Type (2018-2023)
Table 27. Global Myelodysplastic Syndrome Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Myelodysplastic Syndrome Revenue Market Share by Type (2024-2033)
Table 29. Global Myelodysplastic Syndrome Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Myelodysplastic Syndrome Revenue Market Share by Application (2018-2023)
Table 31. Global Myelodysplastic Syndrome Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Myelodysplastic Syndrome Revenue Market Share by Application (2024-2033)
Table 33. North America Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Myelodysplastic Syndrome Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Myelodysplastic Syndrome Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Myelodysplastic Syndrome Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Myelodysplastic Syndrome Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Myelodysplastic Syndrome Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Myelodysplastic Syndrome Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Myelodysplastic Syndrome Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Myelodysplastic Syndrome Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Myelodysplastic Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Myelodysplastic Syndrome Market Size by Country (2024-2033) & (US$ Million)
Table 48. Celgene Company Detail
Table 49. Celgene Business Overview
Table 50. Celgene Myelodysplastic Syndrome Product
Table 51. Celgene Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 52. Celgene Recent Development
Table 53. Novartis Company Detail
Table 54. Novartis Business Overview
Table 55. Novartis Myelodysplastic Syndrome Product
Table 56. Novartis Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 57. Novartis Recent Development
Table 58. Otsuka Company Detail
Table 59. Otsuka Business Overview
Table 60. Otsuka Myelodysplastic Syndrome Product
Table 61. Otsuka Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 62. Otsuka Recent Development
Table 63. Actinium Pharmaceuticals Company Detail
Table 64. Actinium Pharmaceuticals Business Overview
Table 65. Actinium Pharmaceuticals Myelodysplastic Syndrome Product
Table 66. Actinium Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 67. Actinium Pharmaceuticals Recent Development
Table 68. Acceleron Pharma Company Detail
Table 69. Acceleron Pharma Business Overview
Table 70. Acceleron Pharma Myelodysplastic Syndrome Product
Table 71. Acceleron Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 72. Acceleron Pharma Recent Development
Table 73. Bellicum Pharmaceuticals Company Detail
Table 74. Bellicum Pharmaceuticals Business Overview
Table 75. Bellicum Pharmaceuticals Myelodysplastic Syndrome Product
Table 76. Bellicum Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 77. Bellicum Pharmaceuticals Recent Development
Table 78. Cornerstone Pharmaceuticals Company Detail
Table 79. Cornerstone Pharmaceuticals Business Overview
Table 80. Cornerstone Pharmaceuticals Myelodysplastic Syndrome Product
Table 81. Cornerstone Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 82. Cornerstone Pharmaceuticals Recent Development
Table 83. CTI BioPharma Company Detail
Table 84. CTI BioPharma Business Overview
Table 85. CTI BioPharma Myelodysplastic Syndrome Product
Table 86. CTI BioPharma Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 87. CTI BioPharma Recent Development
Table 88. Onconova Therapeutics Company Detail
Table 89. Onconova Therapeutics Business Overview
Table 90. Onconova Therapeutics Myelodysplastic Syndrome Product
Table 91. Onconova Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 92. Onconova Therapeutics Recent Development
Table 93. Strategia Therapeutics Company Detail
Table 94. Strategia Therapeutics Business Overview
Table 95. Strategia Therapeutics Myelodysplastic Syndrome Product
Table 96. Strategia Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 97. Strategia Therapeutics Recent Development
Table 98. KaloBios Pharmaceuticals Company Detail
Table 99. KaloBios Pharmaceuticals Business Overview
Table 100. KaloBios Pharmaceuticals Myelodysplastic Syndrome Product
Table 101. KaloBios Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 102. KaloBios Pharmaceuticals Recent Development
Table 103. Kiadis Pharma Company Detail
Table 104. Kiadis Pharma Business Overview
Table 105. Kiadis Pharma Myelodysplastic Syndrome Product
Table 106. Kiadis Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 107. Kiadis Pharma Recent Development
Table 108. Mirati Therapeutics Company Detail
Table 109. Mirati Therapeutics Business Overview
Table 110. Mirati Therapeutics Myelodysplastic Syndrome Product
Table 111. Mirati Therapeutics Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 112. Mirati Therapeutics Recent Development
Table 113. Astex Company Detail
Table 114. Astex Business Overview
Table 115. Astex Myelodysplastic Syndrome Product
Table 116. Astex Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 117. Astex Recent Development
Table 118. Celator Pharmaceuticals Company Detail
Table 119. Celator Pharmaceuticals Business Overview
Table 120. Celator Pharmaceuticals Myelodysplastic Syndrome Product
Table 121. Celator Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 122. Celator Pharmaceuticals Recent Development
Table 123. Eli-lilly Company Detail
Table 124. Eli-lilly Business Overview
Table 125. Eli-lilly Myelodysplastic Syndrome Product
Table 126. Eli-lilly Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 127. Eli-lilly Recent Development
Table 128. Sunesis Pharmaceuticals Company Detail
Table 129. Sunesis Pharmaceuticals Business Overview
Table 130. Sunesis Pharmaceuticals Myelodysplastic Syndrome Product
Table 131. Sunesis Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 132. Sunesis Pharmaceuticals Recent Development
Table 133. Targazyme Company Detail
Table 134. Targazyme Business Overview
Table 135. Targazyme Myelodysplastic Syndrome Product
Table 136. Targazyme Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 137. Targazyme Recent Development
Table 138. Gamida Cell Company Detail
Table 139. Gamida Cell Business Overview
Table 140. Gamida Cell Myelodysplastic Syndrome Product
Table 141. Gamida Cell Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 142. Gamida Cell Recent Development
Table 143. GlaxoSmithKline Company Detail
Table 144. GlaxoSmithKline Business Overview
Table 145. GlaxoSmithKline Myelodysplastic Syndrome Product
Table 146. GlaxoSmithKline Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 147. GlaxoSmithKline Recent Development
Table 148. Sumitomo Dainippon Pharma Company Detail
Table 149. Sumitomo Dainippon Pharma Business Overview
Table 150. Sumitomo Dainippon Pharma Myelodysplastic Syndrome Product
Table 151. Sumitomo Dainippon Pharma Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 152. Sumitomo Dainippon Pharma Recent Development
Table 153. TetraLogic Pharmaceuticals Company Detail
Table 154. TetraLogic Pharmaceuticals Business Overview
Table 155. TetraLogic Pharmaceuticals Myelodysplastic Syndrome Product
Table 156. TetraLogic Pharmaceuticals Revenue in Myelodysplastic Syndrome Business (2018-2023) & (US$ Million)
Table 157. TetraLogic Pharmaceuticals Recent Development
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myelodysplastic Syndrome Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Myelodysplastic Syndrome Market Share by Type: 2022 VS 2033
Figure 3. Alkylating Agents Features
Figure 4. Cytotoxic Antibiotics Features
Figure 5. Topoisomerase Inhibitors Features
Figure 6. Others Features
Figure 7. Global Myelodysplastic Syndrome Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Myelodysplastic Syndrome Market Share by Application: 2022 VS 2033
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Myelodysplastic Syndrome Report Years Considered
Figure 12. Global Myelodysplastic Syndrome Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Myelodysplastic Syndrome Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Myelodysplastic Syndrome Market Share by Region: 2022 VS 2033
Figure 15. Global Myelodysplastic Syndrome Market Share by Players in 2022
Figure 16. Global Top Myelodysplastic Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome Revenue in 2022
Figure 18. North America Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Myelodysplastic Syndrome Market Share by Country (2018-2033)
Figure 20. United States Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Canada Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Myelodysplastic Syndrome Market Share by Country (2018-2033)
Figure 24. Germany Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. France Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. U.K. Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Italy Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Russia Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Nordic Countries Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Myelodysplastic Syndrome Market Share by Region (2018-2033)
Figure 32. China Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Japan Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. South Korea Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Southeast Asia Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. India Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Australia Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Myelodysplastic Syndrome Market Share by Country (2018-2033)
Figure 40. Mexico Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Brazil Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Myelodysplastic Syndrome Market Share by Country (2018-2033)
Figure 44. Turkey Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Saudi Arabia Myelodysplastic Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Celgene Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 47. Novartis Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 48. Otsuka Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 49. Actinium Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 50. Acceleron Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 51. Bellicum Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 52. Cornerstone Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 53. CTI BioPharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 54. Onconova Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 55. Strategia Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 56. KaloBios Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 57. Kiadis Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 58. Mirati Therapeutics Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 59. Astex Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 60. Celator Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 61. Eli-lilly Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 62. Sunesis Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 63. Targazyme Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 64. Gamida Cell Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 65. GlaxoSmithKline Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 66. Sumitomo Dainippon Pharma Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 67. TetraLogic Pharmaceuticals Revenue Growth Rate in Myelodysplastic Syndrome Business (2018-2023)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed